Core Points - CareCloud, Inc. held its 2025 Annual Shareholders' Meeting on May 27, 2025, where shareholders re-elected Anne Busquet, Bill Korn, and Lawrence Sharnak to the Board for another two-year term [1][2] - Shareholders approved the advisory compensation for the Company's named executive officers as disclosed in the 2025 Proxy Statement [1][7] - Rosenberg Rich Baker Berman, P.A. was appointed as the independent registered public accounting firm for the year ending December 31, 2025 [1][7] Group 1 - Anne Busquet has over 30 years of executive experience with American Express and Interactive Corp [2] - Bill Korn served as Chief Financial Officer for 10 years before retiring in October 2023 [2] - Lawrence Sharnak held various senior leadership roles at American Express for more than 30 years [2] Group 2 - CareCloud provides technology-enabled solutions aimed at improving financial and operational performance, streamlining clinical workflows, and enhancing patient experience [4] - The Company serves over 40,000 providers, helping them improve patient care while reducing administrative burdens and operating costs [4]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36529 CareCloud, Inc. (Exact name of registrant as specified in its charter) Delaware 22-3832302 (I.R.S. Employer Identificatio ...

Exhibit 99.1 CareCloud Delivers Growth and Strong Cash Flow in Q1 2025, Advances AI and Acquisition Strategy SOMERSET, N.J. May 6, 2025 (GLOBE NEWSWIRE) - CareCloud, Inc. (Nasdaq: CCLD, CCLDO), a leader in healthcare technology and generative AI solutions, today announced strong financial results for the three months ended March 31, 2025. CareCloud's strategic execution, AI-driven innovation, and disciplined financial management have fueled a transformational turnaround, positioning the Company for sustaine ...

Core Viewpoint - CareCloud, Inc. has declared monthly cash dividends for its Series A and Series B Preferred Stocks for March and April 2025, reflecting the company's commitment to returning value to shareholders [1][2]. Dividend Details - The monthly dividend for Series A Preferred Stock is $0.18229 per share for both March and April 2025, with an additional payment of $0.04688 per share [2]. - The monthly dividend for Series B Preferred Stock is also $0.18229 per share for both March and April 2025 [2][3]. - The ex-dividend and record dates for both series are March 31, 2025, and April 30, 2025, respectively, with payment dates set for April 15, 2025, and May 15, 2025 [2][4]. Preferred Stock Information - Series A Preferred Stock has a cumulative cash dividend rate of 8.75% per annum based on a $25.00 liquidation preference, equating to $2.1875 per annum per share [2][3]. - Series B Preferred Stock also has a cumulative cash dividend rate of 8.75% per annum based on a $25.00 liquidation preference, equating to $2.1875 per annum per share [3]. - The Series A Preferred Stock was converted into common stock on March 6, 2025, leading to its voluntary delisting from the Nasdaq Global Market [5]. Redemption Options - The company has the option to redeem Series A Preferred Stock at a price of $25.00 per share, plus any accumulated and unpaid dividends, with a notice period of 30 to 60 days [5]. - For Series B Preferred Stock, the redemption prices vary based on the date, starting at $25.50 per share for redemptions on or after February 15, 2025 [6].

Financial Performance - Net revenue for the year ended December 31, 2024, was $110.837 million, a decrease from $117.059 million in 2023, representing a decline of approximately 5.2%[256] - Adjusted EBITDA for 2024 was $24.057 million, significantly up from $15.429 million in 2023, indicating an increase of approximately 55.5%[256] - Adjusted operating income for 2024 was $11.455 million, compared to $5.967 million in 2023, reflecting an increase of approximately 91.5%[259] - The company reported a GAAP net income of $7.851 million for 2024, a substantial improvement from a net loss of $48.674 million in 2023[256] - Non-GAAP adjusted net income for 2024 was $10.520 million, compared to $4.801 million in 2023, marking an increase of approximately 119.1%[259] - The adjusted net income per share for 2024 was $0.65, up from $0.30 in 2023, representing an increase of approximately 116.7%[261] - The GAAP operating margin improved to 8.2% in 2024 from a negative 40.2% in 2023[259] - Operating income for 2024 was $9,121,000, compared to an operating loss of $47,115,000 in 2023[262] - Net income for 2024 was $7,851,000, a significant improvement from a net loss of $48,674,000 in 2023[262] - Net income per common share for 2024 was $(0.28), an improvement from $(4.11) in 2023[262] Expenses and Cost Management - Total operating expenses decreased to $101,716,000 in 2024 from $164,174,000 in 2023, reflecting a reduction of 38%[262] - Direct operating costs for 2024 were $60.8 million, a decrease of $10 million or 14% from $70.8 million in 2023[307] - Selling and marketing expenses decreased by $3.4 million or 35% to $6.2 million in 2024 from $9.7 million in 2023[308] - General and administrative expenses accounted for approximately 22% of total expenses in 2024, up from 17% in 2023, suggesting increased administrative overhead[279] - General and administrative expenses decreased by $5.3 million or 25% to $16.1 million in 2024 from $21.5 million in 2023[309] - Research and development expenses decreased by $955,000 or 20% to $3.8 million in 2024 from $4.7 million in 2023[310] - Total operating expenses for 2024 were $101.7 million, a decrease of $62.5 million or 38% from $164.2 million in 2023[307] Cash Flow and Financial Position - Cash balance increased to $5,145,000 in 2024 from $3,331,000 in 2023[263] - Positive cash flow from operations increased by $5.2 million or 34% to $20.6 million for the year ended December 31, 2024, compared to $15.5 million in 2023[323] - Cash used in investing activities decreased by $4.2 million to $7.4 million in 2024 from $11.6 million in 2023[330] - Cash used in financing activities decreased by $2 million to $11.3 million in 2024 compared to $13.3 million in 2023, including the full repayment of a $10 million credit line[331] Operational Metrics - The company served approximately 40,000 providers across about 2,600 practices as of December 31, 2024, maintaining a stable client base[270] - Customer renewal rates improved to 95% in 2024 from 91% in 2023, reflecting enhanced client retention[271] - Revenue from technology-enabled business solutions accounted for approximately 67% of total revenues in 2024, up from 65% in 2023[272] - Direct operating costs represented approximately 13% of total costs in 2024, compared to 11% in 2023, indicating a slight increase in operational efficiency[277] - The company expects to achieve further economies of scale as it grows, potentially reducing direct operating costs as a percentage of revenue[277] Impairment and Taxation - Goodwill impairment charges in 2023 amounted to $42,000,000, reflecting a significant write-down related to the Healthcare IT reporting unit[282] - The company recorded a goodwill impairment charge of $42 million in 2023, with no such charges in 2024[327] - The income tax provision for 2024 was $160,000, contrasting with a tax benefit of $364,000 in 2023[317] - Total federal NOL carry forward as of December 31, 2024, is approximately $265 million, with $187 million expiring between 2031 and 2038[322] - The company maintained a full valuation allowance on deferred tax assets until sufficient evidence supports the reversal of these allowances[321] Revenue Breakdown - Revenue from technology-enabled business solutions was $73.7 million in 2024, down from $76.6 million in 2023[304] - Professional services revenue decreased by $4.8 million in 2024 compared to 2023, primarily due to the winding down of services for two large accounts[305] - The company generated approximately 1% of its revenue from group purchasing services in both 2024 and 2023, indicating stable performance in this segment[276] - Offshore operations accounted for approximately 15% of total expenses in 2024, up from 9% in 2023, with personnel-related costs making up about 75% of these expenses[251]

Q4 2024 RESULTS Nasdaq Global Market: CCLD, CCLDP, CCLDO March 13, 2025 A leading provider of technology-enabled services and solutions that redefine the healthcare revenue cycle © CareCloud, Inc. 2025 Safe Harbor Statements This presentation contains forward-looking statements within the meaning of the federal securities laws. These statements relate to anticipated future events, future results of operations or future financial performance. In some cases, you can identify forward-looking statements by term ...

Exhibit 99.1 CareCloud Reports Record Breaking Full Year 2024 Net Income Full Year 2024 Performance: An impressive turnaround from 2023 Fourth Quarter 2024: A Strong Finish Recent Operational Wins: "AI is supercharging our operations," said A. Hadi Chaudhry, Co-CEO of CareCloud. "From clinical workflows to revenue cycle automation, AI is making us faster, smarter, and more efficient. This will fuel even greater profitability in 2025." "We've successfully transformed our cost structure and positioned CareClo ...

Financial Performance - For the three months ended September 30, 2024, net revenue was $28,546,000, a decrease of 2.5% from $29,280,000 in the same period of 2023[151]. - Adjusted EBITDA for the nine months ended September 30, 2024, was $16,916,000, an increase of 49.5% compared to $11,301,000 for the same period in 2023[151]. - GAAP net income for the three months ended September 30, 2024, was $3,122,000, compared to a loss of $2,749,000 in the same period of 2023[151]. - Adjusted net income for Q3 2024 was $3.471 million, compared to $203,000 in Q3 2023, reflecting a significant increase[153]. - GAAP net income for Q3 2024 was $3.122 million, a turnaround from a loss of $2.749 million in Q3 2023[153]. - Total revenue for Q3 2024 was $28.546 million, a decrease of 3% from $29.280 million in Q3 2023[170]. - The income before income taxes for the three months ended September 30, 2024, was $3.2 million, compared to a loss of $2.7 million for the same period in 2023[197]. Cost Management - Direct operating costs as a percentage of revenue decreased to 54.0% in Q3 2024 from 62.4% in Q3 2023[170]. - Selling and marketing expenses decreased to 4.8% of revenue in Q3 2024 from 8.0% in Q3 2023[170]. - Direct operating costs decreased by $2.8 million (16%) for the three months and $8.0 million (15%) for the nine months ended September 30, 2024, compared to the same periods in 2023[172]. - Selling and marketing expenses decreased by $962,000 (41%) for the three months and $2.7 million (36%) for the nine months ended September 30, 2024, compared to the same periods in 2023[173]. - General and administrative expenses decreased by $1.1 million (20%) for the three months and $4.4 million (27%) for the nine months ended September 30, 2024, compared to the same periods in 2023[174]. - Research and development expenses decreased by $460,000 (37%) for the three months and $755,000 (21%) for the nine months ended September 30, 2024, compared to the same periods in 2023[175]. Operational Efficiency - Non-GAAP adjusted operating margin for the three months ended September 30, 2024, was 12.9%, compared to 1.8% in the same period of 2023[151]. - The company’s GAAP operating margin for the three months ended September 30, 2024, was 11.4%, compared to a negative margin of 6.7% in the same period of 2023[151]. - The company employs approximately 330 health industry experts in the U.S. and 3,300 offshore team members, achieving significant cost reductions[146]. - The company’s technology solutions include AI-powered clinical decision support and virtual support assistant, enhancing operational efficiency and patient care[145]. Cash Flow and Capital Management - The company had total cash of $2.8 million and net working capital of $732,000 as of September 30, 2024[186]. - Cash provided by operations was $15.4 million, offset by cash used in investing and financing activities of $15.8 million, resulting in a decrease in cash of $549,000 for the nine months ended September 30, 2024[186]. - For the nine months ended September 30, 2024, net cash provided by operating activities was $15.4 million, an increase of 31% compared to $11.7 million for the same period in 2023[198]. - Net cash used in investing activities decreased to $5.1 million for the nine months ended September 30, 2024, down 45% from $9.3 million in 2023[199]. - Net cash used in financing activities was $10.7 million for the nine months ended September 30, 2024, compared to $8.4 million in 2023, reflecting an increase of 27%[200]. - Capital expenditures for the nine months ended September 30, 2024, were $759,000, significantly lower than $2.7 million in 2023[199]. - Software development costs capitalized for the nine months ended September 30, 2024, were $4.4 million, down from $6.6 million in 2023[199]. Market and Operational Insights - Revenue from technology-enabled business solutions accounted for approximately 63% of total revenue in Q3 2024, slightly down from 64% in Q3 2023[157]. - Medical practice management services generated approximately 15% of revenue in Q3 2024, up from 13% in Q3 2023[158]. - The company served approximately 40,000 providers as of September 30, 2024, consistent with the previous year[156]. - The company continues to monitor inflation impacts and believes it can pass on price increases for fixed-rate contracts to customers[195]. Cybersecurity and Risk Management - The company has not identified any compromise or unauthorized access of its systems due to the Change Healthcare cybersecurity incident as of September 30, 2024[192]. - The Company did not experience a material financial impact from the Change Healthcare Cybersecurity Incident on its financial results[193]. - The company has not experienced any losses on cash accounts held at banks in Pakistan and Sri Lanka, despite the lack of deposit insurance coverage in these countries[139]. Future Outlook - Management expects approximately $22.0 million in annualized cost savings, with about $16.0 million realized during 2024[188]. - The company suspended its Preferred Stock dividend in December 2023, leading to a goodwill impairment charge, but as of September 30, 2024, stock prices increased, resulting in no impact on goodwill valuation[140].

Exhibit 99.1 CareCloud Reports Third Quarter 2024 Results Pays Of Credit Line, Plans to Resume Preferred Dividends in Q1 2025 SOMERSET, N.J. November 12, 2024 (GLOBE NEWSWIRE) - CareCloud, Inc. (Nasdaq: CCLD, CCLDO, CCLDP), a leader in healthcare technology and generative AI solutions for medical practices and health systems nationwide, announced financial and operational results for the quarter ended September 30, 2024 including that it has fully paid its credit line and that it plans to resume dividends o ...

Financial Performance - For the three months ended June 30, 2024, net revenue was $28,090,000, a decrease of 4.3% from $29,362,000 in the same period of 2023[153]. - Adjusted EBITDA for the six months ended June 30, 2024, was $10,076,000, an increase of 24.9% compared to $8,056,000 for the same period in 2023[153]. - The company reported a GAAP net income of $1,674,000 for the three months ended June 30, 2024, compared to a loss of $1,832,000 in the same period of 2023[153]. - Non-GAAP adjusted net income for Q2 2024 was $2.958 million, up from $1.410 million in Q2 2023, indicating a year-over-year increase of 109%[156]. - Total revenue for Q2 2024 was $28.1 million, a decrease of 4% from $29.4 million in Q2 2023[173]. - The company reported an income before income taxes of $1.7 million for the three months ended June 30, 2024, compared to a loss of $1.8 million for the same period in 2023[196]. Operational Efficiency - Adjusted operating income for the three months ended June 30, 2024, was $3,249,000, up from $1,724,000 in the same period of 2023, reflecting a significant improvement in operational efficiency[153]. - The adjusted operating margin for the three months ended June 30, 2024, was 11.6%, compared to 5.9% in the same period of 2023, indicating enhanced profitability[153]. - Direct operating costs as a percentage of net revenue decreased to 54.3% in Q2 2024 from 59.5% in Q2 2023, reflecting improved operational efficiency[173]. - Selling and marketing expenses as a percentage of net revenue decreased to 5.9% in Q2 2024 from 8.8% in Q2 2023[173]. - General and administrative expenses as a percentage of net revenue decreased to 14.3% in Q2 2024 from 20.1% in Q2 2023[173]. - Direct operating costs decreased by $2.2 million (13%) and $5.2 million (15%) for the three and six months ended June 30, 2024, compared to the same periods in 2023[175]. Revenue Sources - Revenue from technology-enabled business solutions accounted for approximately 68% of total revenue in Q2 2024, compared to 67% in Q2 2023[160]. - Medical practice management services generated approximately 12% of total revenue in both Q2 2024 and Q2 2023[161]. - Project-based professional services revenue decreased by $1.0 million (13%) and $3.2 million (15%) for the three and six months ended June 30, 2024, compared to the same periods in the prior year[174]. - Revenue from two large accounts contributed to a decline of approximately $1.7 million in revenue for the six months ended June 30, 2024, with revenue from these customers dropping from $2.0 million to $299,000[174]. Cost Management - Personnel-related costs accounted for approximately 76% of total expenses in offshore operations for the six months ended June 30, 2024, providing a competitive advantage due to lower costs[148]. - Selling and marketing expenses decreased by $916,000 (36%) and $1.8 million (34%) for the three and six months ended June 30, 2024, respectively[176]. - General and administrative expenses decreased by $1.9 million (32%) and $3.3 million (30%) for the three and six months ended June 30, 2024, respectively[177]. - Research and development expenses decreased by approximately $130,000 (11%) and $295,000 (13%) for the three and six months ended June 30, 2024, respectively[178]. - Amortization expenses increased by $381,000 (13%) and $1.3 million (23%) for the three and six months ended June 30, 2024, respectively[180]. Cash and Capital Management - As of June 30, 2024, the company had total cash of $2.6 million and net working capital of $674,000[187]. - The company expects approximately $22.0 million in annualized cost savings, with $16.0 million realized during 2024[189]. - Net cash provided by operating activities was $8.3 million, an increase of 13% compared to $7.4 million for the same period in 2023[196]. - Net cash used in investing activities decreased to $3.5 million for the six months ended June 30, 2024, from $6.1 million in 2023, representing a 43% reduction[198]. - Capital expenditures for the six months ended June 30, 2024, were $425,000, down from $1.6 million in 2023[198]. - Software development costs capitalized were $3.0 million for the six months ended June 30, 2024, compared to $4.5 million in 2023[198]. Compliance and Security - The company has not identified any compromise or unauthorized access of its systems due to the Change Healthcare Cybersecurity Incident as of June 30, 2024[193]. - The company has maintained compliance with all covenants under its line of credit as of June 30, 2024[200].